| ￥3300 | |
| Z05235-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 28.4 kDa | ||||
| Apparent Molecular Weight | The protein has a predicted MW of 28.4 kDa same as Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in 4mM HCl (pH 3.0). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Epidermal growth factor-like domain-containing protein 7 (EGFL7), a member of the epidermal growth factor (EGF)-like protein family, is a potent angiogenic factor expressed in many different cell types. EGFL7 plays a vital role in controlling vascular angiogenesis during embryogenesis, organogenesis, and maintaining skeletal homeostasis. |
| Synonyms | EGF-like protein 7; NOTCH4-like protein; VE-statin; NEU1; ZNEU1; EGFL7; MEGF7; MGC111117; RP11-251M1.2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
